Literature DB >> 25342140

Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids.

Marco Mrusek1, Ean-Jeong Seo, Henry Johannes Greten, Michael Simon, Thomas Efferth.   

Abstract

Ergot alkaloids are psychoactive and vasoconstricting agents of the fungus Claviceps purpurea causing poisoning such as ergotism in medieval times (St. Anthony's Fire). This class of substances also inhibits tumor growth in vitro and in vivo, though the underlying mechanisms are unclear as yet. We investigated six ergot alkaloids (agroclavine, ergosterol, ergocornin E, ergotamine, dihydroergocristine, and 1-propylagroclavine tartrate) for their cytotoxicity towards tumor cell lines of the National Cancer Institute, USA. 1-Propylagroclavine tartrate (1-PAT) revealed the strongest cytotoxicity. Out of 76 clinically established anticancer drugs, cross-resistance was found between the ergot alkaloids and 6/7 anti-hormonal drugs (=85.7 %) and 5/15 DNA-alkylating drugs (=33.3 %). The IC50 values for the six alkaloids were not correlated to well-known determinants of drug resistance, such as proliferative activity (as measured by cell doubling times, PCNA expression, and cell cycle distribution), the multidrug resistance-mediating P-glycoprotein/MDR1 and expression or mutations of oncogenes and tumor suppressor genes (EGFR, RAS, TP53). While resistance of control drugs (daunorubicin, cisplatin, erlotinib) correlated with these classical resistance mechanisms, ergot alkaloids did not. Furthermore, COMPARE and hierarchical cluster analyses were performed of mRNA microarray data to identify genes correlating with sensitivity or resistance to 1-PAT. Twenty-three genes were found with different biological functions (signal transducers, RNA metabolism, ribosome constituents, cell cycle and apoptosis regulators etc.). The expression of only 3/66 neuroreceptor genes correlated with the IC50 values for 1-PAT, suggesting that the psychoactive effects of ergot alkaloids may not play a major role for the cytotoxic activity against cancer cells. In conclusion, the cytotoxicity of ergot alkaloids is not involved in classical mechanisms of drug resistance opening the possibility to bypass resistance and to treat otherwise drug-resistant and refractory tumors. The modes of action are multifactorial, which is a typical feature of many natural compounds.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25342140     DOI: 10.1007/s10637-014-0168-4

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  53 in total

1.  Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin.

Authors:  Thomas Efferth; Florian Herrmann; Ahmed Tahrani; Michael Wink
Journal:  Phytomedicine       Date:  2011-08-09       Impact factor: 5.340

Review 2.  Ergotism: a change of persepective.

Authors:  Javier Eduardo Ferrari Ayarragaray
Journal:  Ann Vasc Surg       Date:  2013-08-28       Impact factor: 1.466

Review 3.  The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research.

Authors:  Michael M Gottesman; Victor Ling
Journal:  FEBS Lett       Date:  2005-12-28       Impact factor: 4.124

4.  Synthesis, evaluation of anticancer activity and COMPARE analysis of N-bis(trifluoromethyl)alkyl-N'-substituted ureas with pharmacophoric moieties.

Authors:  Elena L Luzina; Anatoliy V Popov
Journal:  Eur J Med Chem       Date:  2012-03-23       Impact factor: 6.514

5.  Bromocriptine modulates P-glycoprotein function.

Authors:  S Orlowski; D Valente; M Garrigos; E Ezan
Journal:  Biochem Biophys Res Commun       Date:  1998-03-17       Impact factor: 3.575

Review 6.  Post-genome research on the biosynthesis of ergot alkaloids.

Authors:  Shu-Ming Li; Inge A Unsöld
Journal:  Planta Med       Date:  2006-08-10       Impact factor: 3.352

Review 7.  Chemotherapy-induced resistance by ATP-binding cassette transporter genes.

Authors:  Jean-Pierre Gillet; Thomas Efferth; José Remacle
Journal:  Biochim Biophys Acta       Date:  2007-06-06

8.  Clavine alkaloids and derivatives as mutagens detected in the Ames test.

Authors:  H Glatt; H Pertz; R Kasper; E Eich
Journal:  Anticancer Drugs       Date:  1992-12       Impact factor: 2.248

9.  RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis.

Authors:  Barry R Zeeberg; Hongfang Liu; Ari B Kahn; Martin Ehler; Vinodh N Rajapakse; Robert F Bonner; Jacob D Brown; Brian P Brooks; Vladimir L Larionov; William Reinhold; John N Weinstein; Yves G Pommier
Journal:  BMC Bioinformatics       Date:  2011-02-10       Impact factor: 3.307

Review 10.  One, two, three--p53, p63, p73 and chemosensitivity.

Authors:  Martina Müller; Elisa Schulze Schleithoff; Wolfgang Stremmel; Gerry Melino; Peter H Krammer; Tobias Schilling
Journal:  Drug Resist Updat       Date:  2007-02-06       Impact factor: 18.500

View more
  3 in total

1.  Protein Expression Profiling and Virtual Drug Screening as an Approach for Individualized Therapy of Small Cell Vaginal Carcinoma.

Authors:  Mohamed E M Saeed; Hassan E Khalid; Sailesh K Thakur; Thomas Efferth
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

Review 2.  Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence.

Authors:  Shian-Ren Lin; Chia-Hsiang Chang; Che-Fang Hsu; May-Jwan Tsai; Henrich Cheng; Max K Leong; Ping-Jyun Sung; Jian-Chyi Chen; Ching-Feng Weng
Journal:  Br J Pharmacol       Date:  2019-11-27       Impact factor: 8.739

3.  Network Pharmacology and Experimental Verification to Explore the Potential Mechanism of Yin-Huo-Tang for Lung Adenocarcinoma Recurrence.

Authors:  Dianna Liu; Shicheng Lin; Yuan Li; Tian Zhou; Kaiwen Hu; Quanwang Li
Journal:  Drug Des Devel Ther       Date:  2022-02-17       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.